934290-08-1

Upstream product

• 59727-98-9 3-[3,4-di(benzyloxy)phenyl]-2-{[(tert-butoxy)carbonyl]amino}propanoic acid 
• 107-21-1 ethylene glycol 
• 125228-11-7 3-(3,4-bis-benzyloxyphenyl)-2-tert-(butoxycarbonylamino)propionic acid methyl ester 
• 37169-36-1 methyl (S)-2-(tert-butoxycarbonylamino)-3-(3,4-dihydroxyphenyl)propanoate 
• 7101-51-1 L-DOPA methyl ester 
• 59-92-7 levodopa 

Downstream Products

• 913259-56-0 2-tert-butoxycarbonylamino-3-(3,4-dihydroxy-phenyl)-propionic acid 2-[2-tert-butoxycarbonylamino-3-(3,4-dihydroxy-phenyl)-propionyloxy]-ethyl ester 

Relevant academic research and scientific papers

Synthesis and characterization of water-soluble and photostable L-DOPA dendrimers

A small drug molecule, L-DOPA, was converted into well-defined dendritic macromolecules. Their monodisperse nature was shown by NMR, MALDI-TOF-MS, and PAGE. A third-generation L-Dopa dendrimer contained 30 L-Dopa residues, which made up its core, branches, and periphery. Individual L-Dopa moieties in the dendrimer were connected to one another via hydrolyzable diester linkages. These Dopa dendrimers showed a 20-fold increase in aqueous solubility and enhanced photostability in solutions over L-Dopa under identical conditions.

METHOD OF PREPARING DENDRITIC DRUGS

Synthetic design of drug-incorporated novel dendrimer structures for quantitatively controlled drug delivery. The dendritic drugs have better control and thus a quantitative drug release can be obtained. There are no prior art dendritic drugs that control release both sequentially and quantitatively like the dendritic drugs disclosed herein. The dendritic drugs are formed by incorporating multiple same type drug units or more than two different drug types into a dendritic cascade structure to form a dendrimer drug.